Sign in

Filings

Finds words inside filing documents. Searching Eledon Pharmaceuticals, Inc.'s filings · 27 documents indexed.

9 documents · 46 matches

  1. ELDN Eledon Pharmaceuticals, Inc. 10-Q 2025-05-14

    Item 1A. Risk Factors.

    material weakness will not reoccur, or that a new material weakness will not occur in the future. The existence of any material
    3 matches in this document

  2. ELDN Eledon Pharmaceuticals, Inc. 10-K 2026-03-19

    Item 1A. Risk Factors.

    material weakness will not reoccur, or that a new material weakness will not occur in the future. The existence of any material
    7 matches in this document

  3. ELDN Eledon Pharmaceuticals, Inc. 10-Q 2026-05-13

    Item 1A. Risk Factors.

    material weakness will not reoccur, or that a new material weakness will not occur in the future. The existence of any material
    3 matches in this document

  4. ELDN Eledon Pharmaceuticals, Inc. 10-Q 2026-08-13

    Item 1A. Risk Factors.

    material weakness will not reoccur, or that a new material weakness will not occur in the future. The existence of any material
    3 matches in this document

  5. ELDN Eledon Pharmaceuticals, Inc. 10-K/A 2025-08-14

    Item 9A. Controls and Procedures.

    material weakness (the “Prior Year’s Material Weakness”) identified in our internal control over financial reporting related to our accounting
    11 matches in this document

  6. ELDN Eledon Pharmaceuticals, Inc. 10-Q 2025-11-14

    Item 1A. Risk Factors.

    material weakness in our internal control over financial reporting. In addition, a material weakness in our internal control over financial
    6 matches in this document

  7. ELDN Eledon Pharmaceuticals, Inc. 10-Q 2025-08-14

    Item 1A. Risk Factors.

    material weakness in our internal control over financial reporting. In addition, a material weakness in our internal control over financial
    6 matches in this document

  8. ELDN Eledon Pharmaceuticals, Inc. 10-Q/A 2025-08-14

    Item 1A. Risk Factors.

    material weakness in our internal control over financial reporting. In addition, a material weakness in our internal control over financial
    6 matches in this document

  9. ELDN Eledon Pharmaceuticals, Inc. 8-K 2025-08-14

    Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

    material weakness in its internal control over financial reporting related to its accounting for equity instruments. Due to the material
    1 match in this document

Page 1 of 1 · 9 documents